

# Epilepsy- Competitive Landscape, Market and Pipeline Analysis, 2018

<https://marketpublishers.com/r/E98CBF5CD46EN.html>

Date: October 2018

Pages: 147

Price: US\$ 7,500.00 (Single User License)

ID: E98CBF5CD46EN

## Abstracts

This report can be delivered to the clients within 48 hours

'Epilepsy- Competitive Landscape, Market and Pipeline Analysis, 2018', report provides comprehensive insights about marketed and pipeline drugs across this indication. The report provides the detailed analysis of 115+ products along with 45+ companies involved. Ultragenyx Pharmaceuticals, Takeda, and Pfizer are among the developers of most promising pipeline products.

Products covered by Phase

Marketed Products

Phase III, Phase II and Phase I

Pre-clinical, Discovery and Unknown Phase

Overview of pipeline development activities for Epilepsy

Pipeline analysis of 115+ therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details. Report contains the development and sale activities for marketed drugs.

Therapeutic segmentation of products for Epilepsy

The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this Immunotherapy.

## **METHODOLOGY**

Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts.

Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

## **SCOPE**

The report provides competitive pipeline landscape of Epilepsy

The report provides the marketed drugs information including its sales, development activities and details of patent expiry

The report provides the insight of current and future market for Epilepsy

The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information

Coverage of the Epilepsy pipeline on the basis of target, MOA, route of administration, technology involved and molecule type

The report reviews key players involved in the therapeutics development for Epilepsy and also provide company profiling

Pipeline products coverage based on various stages of development ranging from late stage till discovery stage

Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

## REASONS TO BUY

Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage

Establish a comprehensive understanding of the current pipeline scenario Epilepsy to formulate effective R&D strategies

Assess challenges and opportunities that influence Epilepsy R&D

Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage

Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine

Devise corrective measures for pipeline projects by understanding Epilepsy pipeline depth and focus of indication therapeutics

Developing strategic initiatives to support your drug development activities

Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Epilepsy to enhance and expand business potential and scope

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive drugs

Gaining a full picture of the Competitive Landscape for Evidence based Decisions

## Contents

Executive Summary  
Overview  
Competitive Landscape  
Marketed Products  
Drug Description  
Commercial Activities  
Product Profile  
Vimpat Sales  
(The list Continues)  
Pipeline Therapeutics  
Late Stage Products  
Comparative Analysis  
Cannabidiol: INSYS Therapeutics  
Product Description  
Research and Development  
Product Development Activities  
(The list continues)  
Mid Stage Products (Phase II)  
Comparative Analysis  
Early Stage Products (Phase I)  
Comparative Analysis  
Therapeutic Assessment: Phase Products  
Assessment by Monotherapy Products  
Assessment by Route of Administration  
Assessment by Stage and Route of Administration  
Assessment by Molecule Type  
Assessment by Stage and Molecule Type  
Pre-clinical, Discovery and Unknown Products  
Comparative Analysis  
Dormant & Discontinued Products  
Comparative Analysis  
Market Drivers and Barriers  
Appendix

## List Of Tables

### LIST OF TABLES

Table 1: Total Products for Epilepsy

Table 2: Late Stage Products (Phase III)

Table 3: Mid Stage Products (Phase II)

Table 4: Early Stage Products (Phase I)

Table 5: Assessment by Monotherapy Products

Table 6: Assessment by Route of Administration

Table 7: Assessment by Stage and Route of Administration

Table 8: Assessment by Molecule Type

Table 9: Assessment by Stage and Molecule Type

Table 10: Pre-clinical, Discovery and Unknown Stage Products

Table 11: Dormant & Discontinued Products

## List Of Figures

### LIST OF FIGURES

- Figure 1: Pathophysiology of Epilepsy
- Figure 2: Vimpat-Historical Sales (2012-2017)
- Figure 3: Lyrica-Historical Sales (2012-2017)
- Figure 4: Keppra-Historical Sales (2012-2017)
- Figure 5: Keppra-Historical Sales (2012-2017)
- Figure 6: Topamax-Historical Sales (2012-2017)
- Figure 7: Lamictal-Historical Sales (2012-2017)
- Figure 8: Neurontin-Historical Sales (2012-2017)
- Figure 9: Zonegran-Historical Sales (2012-2017)
- Figure 10: Trileptal-Historical Sales (2012-2017)
- Figure 11: Zebinix-Historical Sales (2012-2017)
- Figure 12: Fycompa-Historical Sales (2012-2017)
- Figure 13: Total Products for Epilepsy
- Figure 14: Late Stage Products (Phase III)
- Figure 15: Mid Stage Products (Phase II)
- Figure 16: Early Stage Products (Phase I)
- Figure 17: Assessment by Monotherapy Products
- Figure 18: Assessment by Route of Administration
- Figure 19: Assessment by Stage and Route of Administration
- Figure 20: Assessment by Molecule Type
- Figure 21: Assessment by Stage and Molecule Type
- Figure 22: Pre-clinical, Discovery and Unknown Stage Products
- Figure 23: Dormant & Discontinued Products

## I would like to order

Product name: Epilepsy- Competitive Landscape, Market and Pipeline Analysis, 2018

Product link: <https://marketpublishers.com/r/E98CBF5CD46EN.html>

Price: US\$ 7,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E98CBF5CD46EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970